Exciting Times for Aclarion and Nociscan Expansion
Aclarion, Inc. (NASDAQ: ACON, ACONW) is making waves in the healthcare technology sector with its innovative approach to chronic low back pain management. The company has recently announced its plans to expand the availability of Nociscan, a groundbreaking technology aimed at providing physicians with critical insights into the causes of back pain. This expansion focuses on markets in New York and New Jersey, enhancing access for patients in these key areas.
Growth of Nociscan in Strategic Locations
With a strong foundation already established in partnership with RadNet affiliates, Aclarion's expansion seems timely given the increasing demand for non-invasive diagnostic tools. Nociscan utilizes advanced MR Spectroscopy (MRS) technology, enabling physicians to better identify which lumbar discs are associated with pain, ultimately streamlining treatment plans for patients suffering from chronic low back pain.
Strengthening Partnerships with RadNet
This expansion effort reflects Aclarion's commitment to improving patient outcomes through enhanced diagnostics. Brent Ness, the CEO of Aclarion, highlighted the importance of expanding scanner access to make Nociscan a part of standard care for those with chronic low back pain. The new locations will provide more convenience, facilitating greater access to Nociscan's technology and increasing scan volumes to meet physician demand.
Highlighting Key Facilities
Among the notable facilities, Lenox Hill Radiology (LHR) operates numerous outpatient centers in the New York metropolitan area, contributing significantly to the treatment landscape. Specifically, LHR Park Avenue has been an early adopter of Nociscan, aiming to provide unparalleled access to spine specialists and esteemed institutions like Weill Cornell. Similarly, New Jersey Imaging Network (NJIN) stands out as a major imaging provider, enhancing patient care with Nociscan adoption at its NJIN-Union location. This site provides essential services for local physicians and those traveling for care, thanks to its proximity to major transportation hubs.
The Impact of Chronic Low Back Pain
Chronic low back pain affects millions globally, creating a significant healthcare challenge. An estimated 266 million people face degenerative spine issues, and Aclarion is addressing this need head-on with its Nociscan solution. As the first SaaS platform of its kind, Nociscan aids physicians in distinguishing between discs that cause pain and those that do not. By quantifying chemical biomarkers related to disc pain, it offers a deeper understanding of the condition and boasts an impressive 97% surgical success rate when addressing pain-positive discs identified by the technology.
The Nociscan Advantage
Nociscan's innovative method involves receiving data through a cloud connection from MRI machines. Proprietary signal processing techniques analyze this data to provide insights about the potential pain sources. By integrating Nociscan with existing diagnostic measures, physicians gain essential clarity that helps optimize treatment strategies for their patients.
A Focus on the Future
As Aclarion continues to expand its reach, the implications for patients suffering from chronic low back pain are profound. The company's proactive steps not only enhance access to cutting-edge diagnostics but also foster stronger ties with significant imaging providers like RadNet. With plans firmly in place, Aclarion is set to become a leader in the healthcare technology landscape as it aims to transform the way chronic pain is approached and treated.
Frequently Asked Questions
What is Nociscan?
Nociscan is a healthcare technology platform that helps physicians identify painful lumbar discs using Magnetic Resonance Spectroscopy.
Why is Aclarion expanding Nociscan availability?
The expansion aims to increase access for patients suffering from chronic low back pain and meet rising demand for this advanced diagnostic tool.
How does Nociscan work?
Nociscan analyzes MRS data to differentiate between painful and non-painful discs in the lumbar spine, providing valuable insights for treatment planning.
What is the surgical success rate of Nociscan?
The technology demonstrates a 97% surgical success rate when addressing discs identified as pain-positive.
Who can benefit from Nociscan?
Patients with chronic low back pain seeking accurate diagnosis and treatment options can greatly benefit from Nociscan and its non-invasive approach.
